In silico drug profiling of the human kinome based on a molecular marker for cross reactivity

Molecular Pharmaceutics

Volumn 5, Issue 5, 2008, Pages 728-738

  Zhang, Xi ^a   Fernández, Ariel ^a,b  

^a RICE UNIVERSITY   (United States)

^b Rice University   (United States)

Author keywords

Affinity profile; Cancer therapy; Computational screening; Human kinase; Lead compound

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CANERTINIB; DORAMAPIMOD; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; IMATINIB; LAPATINIB; MOLECULAR MARKER; PROTEIN KINASE; ROSCOVITINE; RUBOXISTAURIN; SORAFENIB; VANDETANIB;

ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CROSS REACTION; DRUG TARGETING; ENZYME INHIBITION; ENZYME STRUCTURE; HIGH THROUGHPUT SCREENING; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; STRUCTURAL HOMOLOGY; VALIDITY;

ALGORITHMS; BIOLOGICAL MARKERS; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; PREDICTIVE VALUE OF TESTS; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 56049119878     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800010p     Document Type: Article

References (26)

1. Drews, J. Drug Discovery: A Historical Perspective. Science 2000, 287, 1960-1964.
2. Bleicher, K. H.; Böhm, H. J.; Muller, K.; Alanine, A. I. Hit and lead generation: Beyond high-throughput screening. Nat. Rev. 2003, 2, 369-378.
3. Liszewski, K. Drug Discovery: Successful Lead Optimization Strategies. Genet. Eng. Biotechonol. News 2006, 26, 14.
4. Fabian, M. A.; Biggs, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
5. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat. Rev. 2004, 3, 935-949.
6. Shoichet, B. B. Virtual screening of chemical libraries. Nature 2004, 432, 862-865.
7. Oprea, T. I.; Matter, H. Integrating virtual screening in lead discovery. Curr. Opin. Chem. Biol. 2004, 8, 349-358.
8. Lengauer, T.; Lemmen, C.; Rarey, M.; Zimmermann, M. Novel technologies for virtual screening. Drug Discovery Today 2004, 9, 27-34.
9. Lyne, P. D. Structure-based virtual screening: An overview. Drug Discovery Today 2002, 7, 1047-1055.
10. Kuhn, P.; Wilson, K.; Patch, M. G.; Stevens, R. C. The genesis of high-throughput structure-based drug discovery using protein crystallography. Curr. Opin. Chem. Biol. 2002, 6, 704-710.
11. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases. Cell 2002, 109, 275-282.
12. Mizutani, M. Y.; Itai, A. Efficient Method for High-Throughput Virtual Screening Based on Flexible Docking: Discovery of Novel Acetylcholinesterase Inhibitors. J. Med. Chem. 2004, 47, 4818-4828.
13. Mizutani, M. Y.; Takamatsu, Y.; Ichinose, T.; Nakamura, K.; Itai, A. Effective Handling of Induced-Fit Motion in Flexible Docking. Protein: Struct., Funct., Bioinf. 2006, 63, 878-891.
14. Chen, J.; Zhang, X.; Fernández, A. Molecular basis for promiscuity and specificity in the druggable kinome. Bioinformatics 2007, 23, 563-572.
15. Bain, J.; McLauchlan, H.; Eliott, M.; Cohen, P. The specificities of protein kinase inhibitors: An update. Biochem. J. 2003, 371, 199-204.
16. Druker, B. J. Molecularly targeted therapy: Have the floodgates opened. Oncologist 2004, 9, 357-360.
17. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136.
18. Knight, Z. A.; Shokat, K. M. Features of Selective Kinase Inhibitors. Chem. Biol. 2005, 12, 621-637.
19. Vieth, M.; Higgs, R. E.; Robertson, D. H.; Shapiro, M.; Gragg, E. A.; Hemmerle, H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 2004, 1697, 243-257.
20. Fernández, A. Keeping Dry and crossing membranes. Nat. Biotechnol. 2004, 22, 1081-1084.
21. Fernández, A.; Berry, R. S. Molecular dimension explored in evolution to promote proteomic complexity. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 13460-13465.
22. Fernández, A.; Maddipati, S. A priori inference of cross reactivity for drug-targeted kinases. J. Med. Chem. 2006, 49, 3092-3100.
23. Fernández, A.; Sanguino, A.; Peng, Z.; Ozturk, E.; Chen, J.; Crespo, A.; Wulf, S.; Shavrin, A.; Qin, C.; Ma, J.; Trent, J.; Lin, Y.; Han, H. D.; Mangala, L. S.; Bankson, J. A.; Gelovani, J.; Samarel, A.; Bornmann, W.; Sood, A. K.; Lopez-Berestein, G. An anticancer C-kit kinase inhibitor is re-engineered to make it more active and less cardiotoxic. J. Clin. Invest. 2007, 117, 4044-4054.
24. Crespo, A.; Fernández, A. Kinase packing defects as drug targets. Drug Discovery Today 2007, 12, 917-923.
25. Kerkela, R.; Grazette, L.; Yacobi, R.; Iliescu, C.; Patten, R.; Beahm, C.; Walters, B.; Shevtsov, S.; Pesant, S.; Clubb, F. J.; Rosenzweig, A.; Salomon, R. N.; Van Etten, R. A.; Alroy, J.; Durand, J.-B.; Force, T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 2006, 12, 908-916.
26. Rockey, W. M.; Elcock, A. H. Rapid Computational Identification of the Targets of Protein Kinase Inhibitors. J. Med. Chem. 2005, 48, 4138-4152.